Citations

Showing 10 of 108119 citations.

Remote synchronous toenail procedure training using a sausage model
Stacey, Stephen K , Malone, Edward J.

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | November 15, 2021 | Volume: 11 | Issue: 6 | Pages: 808-811

10.1080/20009666.2021.1976371 | PMID 34804395 Get It

In vitro and in vivo effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA‑4, in B‑cell acute lymphoblastic leukemia
Ruan, Yongsheng , Kim, Hye Jin , Ogana, Heather , Gang, Eun Ji , Bhojwani, Deepa, Wayne, Alan S. , Kim, Yong‐Mi , Bhojwani, Deepa , Kim, Hye Na , Liu, Hsiao‐Chuan , Li, Shuangyue , Yang, Mo

Mayo Clinic

Experimental and Therapeutic Medicine | November 15, 2021 | Volume: 23 | Issue: 1 | Pages: No page available

10.3892/etm.2021.10969 | PMID 34934426 Get It

mTOR-Dependent ARID1A Degradation: A New Twist in the Genetic–Epigenetic Interplay Driving Hepatocellular Carcinoma
Pease, David R., Fernandez-Zapico, Martin E., Pease, David R., Fernandez-Zapico, Martin E.

Mayo Clinic

Cancer Research | November 15, 2021 | Volume: 81 | Issue: 22 | Pages: 5608-5610

10.1158/0008-5472.can-21-3226 | PMID 34782322 Get It

Abstract The importance of the cross-talk between the genetic and epigenetic alterations promoting cancer development is well understood; however, the molecular details underlying the mechanism of how oncogenic signaling remodels the epigenome to generate a procancer transcriptome require further elucidation. The study by Zhang and colleagues in this issue of Cancer Research reveals a novel role for oncogenic mTOR signaling leading to the degradation of a prominent chromatin remodeler, ARID1a, establishing an altered, protumor chromatin landscape in hepatocellular carcinoma (HCC) controlling tumor deve-lopment and treatment resistance. These findings highlight oncogenic effects on chromatin remodelers as an important factor in both HCC pathobiology and therapeutic response. As strategies for cancer therapy begin to move in an increasingly individualized direction, increased knowledge into the impact of restoring the function of chromatin remodelers on response to therapy is warranted. See related article by Zhang et al., p. 5652
Abstract PO-013: Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment and TEsting (GENERATE) study
Rodriguez, Nicolette J. , Furniss, C. Sloane , Yurgelun, Matthew B. , Constantinou, Pamela E., Stopfer, Jill E. , Kenner, Barbara , Nelson, Scott H., Okumura, Sydney, Law, Sherman , Coffin, Tara B. , Ocean, Allyson J. , McAllister, Florencia , Lowy, Andrew M. , Lippman, Scott M. , Madlensky, Lisa , Petersen, Gloria M. , Ukaegbu, Chinedu I. , Schwartz, Alison , Underhill‐Blazey, Meghan , Nelson, Scott, Zhou, Alicia Yiran , Uno, Hajime , Klein, Alison P. , Garber, Judy E. , Goggins, Michael , Maitra, Anirban , Syngal, Sapna

Mayo Clinic

Cancer Research | November 15, 2021 | Volume: 81 | Issue: 22_Supplement | Pages: PO-013-PO-013

10.1158/1538-7445.panca21-po-013 Get It

Abstract Background: Roughly 7–10% of patients with pancreatic ductal adenocarcinoma (PDAC) have a deleterious germline variant. Although identification of germline variants in family members has implications for cancer surveillance and can lead to early cancer detection and interception for PDAC, as well as other cancers, cascade genetic testing rates are low. The GENetic Education, Risk Assessment and TEsting (GENERATE) study evaluates novel methods of providing genetic education and testing for individuals at risk for hereditary PDAC. Methods: Eligible participants had: (1) a first- or second-degree relative with a diagnosis of PDAC and a known familial germline variant in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53 (Known Familial Mutation (KFM)), (2) or were first-degree relatives of PDAC patients (no KFM). Participants were recruited through six academic centers, patient advocacy organizations and online outreach. Enrollment occurred through the study website (www.GENERATEstudy.org). All study participation, including genetic testing via a at home saliva sample kit, was done remotely. Participants were cluster randomized at the family level into one of two arms. Arm 1 (Doxy.me plus Color Genomics) included remote genetic education and testing through a video-based telemedicine platform (Doxy.me) and physician-mediated testing through Color Genomics. Arm 2 included remote genetic education and testing through Color Genomics only. Results: Between 5/8/2019–6/01/2021, 423 families were randomized, comprising 595 participants. Recruitment occurred through patient invitation via healthcare providers (n=128, 21.5%), family members (n=271, 45.5%), friends, advocacy groups, and online outreach (n=223, 37.5%). Participants were referred from the six GENERATE academic centers (n=270, 45.4%) and other institutions (n=325, 54.6%). Study participants were 52.5 years on average, primarily identified as White (n=577, 97%) and from the Northeast (n=184, 30.9%), Midwest (n=154, 25.9%), South (n=158, 26.6%) and West (n=99, 16.6%). Participants were randomized into each arm (n=296 Doxy.me plus Color Genomics; n=299 Color Genomics only). To date, 527 (88.6%) participants have ordered genetic testing. The uptake of genetic testing was 253/296 (85.5%) in the Doxy.me plus Color Genomics arm and 274/299 (91.6%) in the Color Genomics only arm (p=0.049, generalized mixed-effects model). A total of 82 PDAC associated pathogenic variants were identified. The most frequently detected variants were BRCA2 (n=32), ATM (n=25) and PALB2 (n=6). Additionally, 13 non-PDAC associated pathogenic variants and 20 low penetrance variants were detected. Conclusions: Remote methods of genetic education and testing are successful alternatives to traditional cascade testing, with genetic testing rates nearly 90%. Participant follow up will assess if satisfaction with decision making, cancer-risk distress, knowledge gained, family communication, and uptake of surveillance were impacted by the mode of delivery of pre-test genetic education. Citation Format: Nicolette J. Rodriguez, Constance S. Furniss, Matthew B. Yurgelun, Chinedu Ukaegbu, Pamela E. Constantinou, Alison N. Schwartz, Jill Stopfer, Meghan Underhill-Blazey, Barbara Kenner, Scott Nelson, Sydney Okumura, Sherman Law, Alicia Y. Zhou, Tara B. Coffin, Hajime Uno, Allyson Ocean, Florencia McAllister, Andrew M. Lowy, Scott M. Lippman, Alison P. Klein, Lisa Madlensky, Gloria M. Petersen, Judy E. Garber, Michael G. Goggins, Anirban Maitra, Sapna Syngal. Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment and TEsting (GENERATE) study [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-013.
Surgical evaluation in children
Perry, Μ. Scott , Shandley, Sabrina, Singh, Rani K. , Sullivan, Joseph , Gonzalez‐Giraldo, Ernesto , Romanowski, Erin Fedak , McNamara, Nancy , Marashly, Ahmad , Ostendorf, Adam P. , Alexander, Allyson , Eschbach, Krista , Bolton, Jeffrey , McGoldrick, Patricia E. , Depositario‐Cabacar, Dewi F., Ciliberto, Michael A. , Gedela, Satyanarayana , Sannagowdara, Kumar , Karia, Samir , Shrey, Daniel W. , Tatachar, Priya, Nangia, Srishti, Reddy, Shilpa B. , Shital, Patel, Coryell, Jason , Perry, Michael Scott , Wong-Kisiel, Lily, Eschbach, Krista , Grinspan, Zachary , Reddy, Shilpa B , Coryell, Jason , Gonzalez-Giraldo, Ernesto , McNamara, Nancy A , Perelman, Maxim , Wong‐Kisiel, Lily C. , Wolf, Steven M. , Depositario‐Cabacar, Dewi, Grinspan, Zachary M.

Mayo Clinic

Epilepsia | November 15, 2021 | Volume: 63 | Issue: 1 | Pages: 96-107

10.1111/epi.17124 | PMID 34778945 Get It

AbstractObjectiveDrug‐resistant epilepsy (DRE) occurs at higher rates in children <3 years old. Epilepsy surgery is effective, but rarely utilized in young children despite developmental benefits of early seizure freedom. The present study aims to identify unique patient characteristics and evaluation strategies in children <3 years old who undergo epilepsy surgery evaluation as a means to assess contributors and potential solutions to health care disparities in this group.MethodsThe Pediatric Epilepsy Research Consortium Epilepsy Surgery Database, a multicentered, cross‐sectional collaboration of 21 US pediatric epilepsy centers, collects prospective data on children <18 years of age referred for epilepsy surgery evaluation. We compared patient characteristics, diagnostic utilization, and surgical treatment between children <3 years old and those older undergoing initial presurgical evaluation. We evaluated patient characteristics leading to delayed referral (>1 year) after DRE diagnosis in the very young.ResultsThe cohort included 437 children, of whom 71 (16%) were <3 years of age at referral. Children evaluated before the age of 3 years more commonly had abnormal neurological examinations (p = .002) and daily seizures (p = .001). At least one ancillary test was used in 44% of evaluations. Fifty‐nine percent were seizure‐free following surgery (n = 34), with 35% undergoing limited focal resections. Children with delayed referrals more often had focal aware (p < .001) seizures and recommendation for palliative surgeries (p < .001).SignificanceThere are relatively few studies of epilepsy surgery in the very young. Surgery is effective, but may be disproportionally offered to those with severe presentations. Relatively low utilization of ancillary testing may contribute to reduced surgical therapy for those without evident lesions on magnetic resonance imaging. Despite this, a sizeable portion of patients have favorable outcome after focal epilepsy surgery resections.
Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary
Al-Makki, Akram , DiPette, Donald, Whelton, Paul K. , Murad, M. Hassan, Acharya, Shrish, Beheiry, Hind Mamoun, Champagne, Beatriz, Connell, Kenneth , Cooney, Marie Therese, Ezeigwe, Nnenna, Gaziano, Thomas Andrew , Gidio, Agaba, Lopez-Jaramillo, Patricio, Khan, Unab I., Kumarapeli, Vindya , Moran, Andrew E., Silwimba, Margaret Mswema, Sukonthasan, Apichard, Yu, Jing, Saraffzadegan, Nizal, Reddy, K. Srinath, Khan, Taskeen, Reddy, K. Srinath , Mustafa, Reem A , Connell, Kenneth , Gaziano, Thomas Andrew , Kumarapeli, Vindya , Rayner, Brian , Al-Makki, Akram , DiPette, Donald, Whelton, Paul K , Murad, M. Hassan, Acharya, Shrish, Beheiry, Hind Mamoun, Champagne, Beatriz, Cooney, Marie Therese , Ezeigwe, Nnenna, Gidio, Agaba, Lopez-Jaramillo, Patricio, Khan, Unab I., Moran, Andrew E., Silwimba, Margaret Mswema, Sukonthasan, Apichard, Yu, Jing, Saraffzadegan, Nizal, Reddy, K. Srinath, Khan, Taskeen

Mayo Clinic

Hypertension | November 15, 2021 | Volume: 79 | Issue: 1 | Pages: 293-301

10.1161/hypertensionaha.121.18192 | PMID 34775787 Get It

Hypertension is a major cause of cardiovascular disease and deaths worldwide especially in low- and middle-income countries. Despite the availability of safe, well-tolerated, and cost-effective blood pressure (BP)-lowering therapies, <14% of adults with hypertension have BP controlled to a systolic/diastolic BP <140/90 mm Hg. We report new hypertension treatment guidelines, developed in accordance with the World Health Organization Handbook for Guideline Development. Overviews of reviews of the evidence were conducted and summary tables were developed according to the Grading of Recommendations, Assessment, Development, and Evaluations approach. In these guidelines, the World Health Organization provides the most current and relevant evidence-based guidance for the pharmacological treatment of nonpregnant adults with hypertension. The recommendations pertain to adults with an accurate diagnosis of hypertension who have already received lifestyle modification counseling. The guidelines recommend BP threshold to initiate pharmacological therapy, BP treatment targets, intervals for follow-up visits, and best use of health care workers in the management of hypertension. The guidelines provide guidance for choice of monotherapy or dual therapy, treatment with single pill combination medications, and use of treatment algorithms for hypertension management. Strength of the recommendations was guided by the quality of the underlying evidence; the tradeoffs between desirable and undesirable effects; patient’s values, resource considerations and cost-effectiveness; health equity; acceptability, and feasibility consideration of different treatment options. The goal of the guideline is to facilitate standard approaches to pharmacological treatment and management of hypertension which, if widely implemented, will increase the hypertension control rate world-wide.
Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Asrani, Sumeet K. , Ghabril, Marwan , Kuo, Alexander , Merriman, Raphael B., Morgan, Timothy R. , Parikh, Neehar D. , Ovchinsky, Nadia , Kanwal, Fasiha , Volk, Michael L. , Ho, Chanda , Mehta, Shivang , Cabrera, Roniel , Chernyak, Victoria , El‐Serag, Hashem B. , Ioannou, George N. , Marrero, Jorge A. , Mehta, Neil , Walling, Anne M. , Tapper, Elliot B. , Ghabril, Marwan S , Morgan, Timothy , Serper, Marina , Agopian, Vatche G , Ioannou, George N , Singal, Amit , Salem, Riad , Asrani, Sumeet K , Ovchinsky, Nadia , Parikh, Neehar D , Serper, Marina , Agopian, Vatche G. , Heimbach, Julie K. , Kaplan, David E. , Singal, Amit G. , Taddei, Tamar H

Mayo Clinic

Hepatology | November 15, 2021 | Volume: 75 | Issue: 5 | Pages: 1289-1299

10.1002/hep.32240 | PMID 34778999 Get It

Abstract The burden of HCC is substantial. To address gaps in HCC care, the American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) aimed to develop a standard set of process‐based measures and patient‐reported outcomes (PROs) along the HCC care continuum. We identified candidate process and outcomes measures for HCC care based on structured literature review. A 13‐member panel with content expertise across the HCC care continuum evaluated candidate measures on importance and performance gap using a modified Delphi approach (two rounds of rating) to define the final set of measures. Candidate PROs based on a structured scoping review were ranked by 74 patients with HCC across 7 diverse institutions. Out of 135 measures, 29 measures made the final set. These covered surveillance (6 measures), diagnosis (6 measures), staging (2 measures), treatment (10 measures), and outcomes (5 measures). Examples included the use of ultrasound (± alpha‐fetoprotein [AFP]) every 6 months, need for surveillance in high‐risk populations, diagnostic testing for patients with a new AFP elevation, multidisciplinary liver tumor board (MLTB) review of Liver Imaging‐Reporting and Data System 4 lesions, standard evaluation at diagnosis, treatment recommendations based on Barcelona Clinic Liver Cancer staging, MLTB discussion of treatment options, appropriate referral for evaluation of liver transplantation candidacy, and role of palliative therapy. PROs include those related to pain, anxiety, fear of treatment, and uncertainty about the best individual treatment and the future. The AASLD PMC has developed a set of explicit quality measures in HCC care to help bridge the gap between guideline recommendations and measurable processes and outcomes. Measurement and subsequent implementation of these metrics could be a central step in the improvement of patient care and outcomes in this high‐risk population.
Connective Tissue Disease Patients Maintain Greater Distraction During Growth Friendly Surgery
Marrache, Majd , Suresh, Krishna V. , White, Klane K. , Larson, A. Noelle , Sponseller, Paul D.

Mayo Clinic

Journal of Pediatric Orthopaedics | November 14, 2021 | Volume: 42 | Issue: 2 | Pages: e188-e191

10.1097/bpo.0000000000002003 | PMID 34995261 Get It

Study Design: Multicenter retrospective study. Background: Recent studies have demonstrated diminishing returns in patients with early onset scoliosis (EOS) undergoing repeated lengthening of growing rods. Little is known about whether this same phenomenon occurs in patients with lax connective tissue disease (CTD). The primary purpose of this study is to investigate whether EOS patients with connective tissue laxity disorders have diminishing returns during growth friendly surgery. Methods: CTD EOS patients below 10 years old, underwent growth friendly spine surgery with distal anchors and at least 1 proximal spine anchor, and had minimum follow-up of 5 years were included in this study. Coronal T1-S1 height at preindex surgery, postindex, and every available lengthening was assessed. Mean coronal height change during early set distractions and late set distractions were calculated for the cohort. To account for varying distraction intervals, we normalized the distractions by the time interval. The outcome parameter was T1-S1 height gain, mm/year. Results: Twenty-one CTD patients were included in this study. Total coronal height (T1-S1) was 26.7MHCcm before index, 32.2 cm at D1-D3, 34.7 cm at D4-D6, and 36.7 cm at D7-L10. There were no significant differences in coronal height gains between early and late distractions (P=0.70). Moreover, when normalized for time, there was no significant difference in net gain per year at different lengthening time points for the CTD group, P=0.59. Conclusion: There is no evidence of diminishing returns in coronal T1-S1 height gain in patients with EOS in the setting of CTD. Level of Evidence: Level III.
Controversial risk factors for cholangiocarcinoma
Baidoun, Firas, Sarmini, Muhammad Talal, Merjaneh, Zahi, Moustafa, Muhamad Alhaj, Baidoun, Firas, Sarmini, Muhammad Talal, Merjaneh, Zahi, Moustafa, Muhamad Alhaj

Mayo Clinic

European Journal of Gastroenterology & Hepatology | November 14, 2021 | Volume: 34 | Issue: 3 | Pages: 338-344

10.1097/meg.0000000000002313 | PMID 34775457 Get It

Introduction Cholangiocarcinoma is a rare malignancy accounting for 3% of gastrointestinal cancers in the USA. While multiple risk factors for cholangiocarcinoma are established, other potential risk factors are still controversial. Herein, we used a large national database to investigate possible risk factors and associations. Method We used the National Inpatient Sample database to review all admissions between 2011 and 2015. We grouped patients based on the presence and absence of cholangiocarcinoma. Using multivariate logistic regression analysis, we assessed the association between obesity, alcohol abuse, smoking, diabetes mellitus and cholangiocarcinoma. Results Out of 30 9552 95 admissions, 20 030 had cholangiocarcinoma. Cholangiocarcinoma patients were older (67 ± 12.8 vs. 57 ± 20.6; P < 0.001) and had fewer female patients (48 vs. 59%; P < 0.001). Multivariate logistic regression analysis showed that diabetes mellitus was associated with cholangiocarcinoma (OR, 1.04; 95% CI, 1.01–1.08; P < 0.001). On the other hand, alcohol, smoking and obesity were all inversely associated with cholangiocarcinoma (OR, 0.75; 95% CI, 0.69–0.81; P < 0.001), (OR, 0.75; 95% CI, 0.71–0.79; P < 0.001) and (OR, 0.71; 95% CI, 0.67–0.75; P < 0.001), respectively. In addition, compared to Whites, Hispanic and Asian/Pacific Islander races were more associated with cholangiocarcinoma (OR, 1.27; 95% CI, 1.21–1.34) and (OR, 1.79; 95% CI, 1.67–1.92) ( P < 0.001 for all), respectively, whereas African American race was inversely associated with cholangiocarcinoma (OR, 0.85; 95% CI, 0.81–0.89; P < 0.001). Conclusion Patients with a diagnosis of diabetes mellitus or from certain ethnic groups (Hispanic and Asian/Pacific Islander) are associated with increased risk for cholangiocarcinoma.
Sentinel Epileptiform Discharges Activating Two Seizure Networks on Intracranial EEG
Lapalme-Remis, Samuel, Payne, Eric T., Brinkmann, Benjamin H., Britton, Jeffrey W., Brinkmann, Benjamin H. , Brinkmann, Benjamin H , Lapalme-Remis, Samuel, Payne, Eric T., Britton, Jeffrey W.

Mayo Clinic

Journal of Clinical Neurophysiology | November 14, 2021 | Volume: 39 | Issue: 3 | Pages: e10-e14

10.1097/wnp.0000000000000872 | PMID 35255009 Get It

Summary: Sentinel epileptiform discharges (SEDs) are epileptiform transients preceding the onset of a focal seizure seen on scalp EEG. Despite their potential localizing value, formal study of SED has been limited. The authors report a patient with MRI-negative focal-onset epilepsy whose seizures on scalp and intracranial EEG were always preceded by SED. Although the location and morphology of the SED was invariable, the seizures after the discharge were of two clearly distinct types, each with different semiology and region of spread on intracranial EEG. This suggests that the SED played a role in activating two distinct seizure networks. A right temporal lobectomy with amygdalohippocampectomy was performed. The resection included both the region of the SED as well as the seizure-onset zone of the more common seizure type, achieving seizure freedom at 3 years after surgery. Further research exploring whether the localization of SED is a reliable indicator of the seizure-onset zone could aid surgical planning in patients whose seizures are preceded by SED.